Renaissance Technologies
ARIA

Renaissance Technologies’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Renaissance Technologies’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-762,481
Closed -$9.48M – 3595
2016
Q4 		$9.48M Sell
762,481
-595,700
-44% -$7.17M 0.02% 1269
2016
Q3 		$18.6M Buy
1,358,181
+1,276,485
+1,562% +$12.8M 0.03% 753
2016
Q2 		$604K Sell
81,696
-415,688
-84% -$3.12M ﹤0.01% 2731
2016
Q1 		$3.18M Sell
497,384
-279,497
-36% -$1.57M 0.01% 1941
2015
Q4 		$4.86M Buy
776,881
+753,242
+3,186% +$4.94M 0.01% 1509
2015
Q3 		$138K Sell
23,639
-2,070,842
-99% -$16M ﹤0.01% 2960
2015
Q2 		$17.3M Sell
2,094,481
-581,000
-22% -$5.14M 0.04% 623
2015
Q1 		$22M Buy
2,675,481
+2,394,100
+851% +$17.7M 0.05% 527
2014
Q4 		$1.93M Sell
281,381
-971,300
-78% -$6.07M ﹤0.01% 1816
2014
Q3 		$6.76M Sell
1,252,681
-3,147,300
-72% -$18.4M 0.02% 1011
2014
Q2 		$28M Buy
4,399,981
+2,151,135
+96% +$14.8M 0.07% 341
2014
Q1 		$18.1M Buy
+2,248,846
New +$17.5M 0.04% 528

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Renaissance Technologies's ARIA Position: Q1 2017 in Review

Renaissance Technologies sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 762,481 shares — an estimated $9.48M sold.

Renaissance Technologies first reported a position in ARIA in Q1 2014 and held it in 12 quarters. The position peaked at $28M in Q2 2014. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Renaissance Technologies reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Renaissance Technologies sold 762,481 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $9.48M.
  • Renaissance Technologies first reported a position in Ariad Pharmaceuticals Inc in Q1 2014 and held it in 12 quarters.
  • Renaissance Technologies's Ariad Pharmaceuticals Inc position peaked at $28M in Q2 2014.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.